BillionToOne, Inc.
(NASDAQ:BLLN) shares fell 28.12% in Wednesday's after-hours session after the company reported its second-quarter financial results.
The stock closed Wednesday's regular session up 5.43% at $149.97 before falling 28.12% to $107.80 in after-hours trading.
BillionToOne is a molecular diagnostics company that develops genetic testing products for prenatal and oncology applications using its proprietary DNA counting technology.
Quarter Results For the quarter ended June 30, 2026, BillionToOne reported revenue of $109.4 million, up from $66.6 million in the prior-year period.
